[go: up one dir, main page]

MA30419B1 - Utilisation de derives de n-(2-thiazolyl)-amides en tant qu'inhibiteurs de la gsk-3 - Google Patents

Utilisation de derives de n-(2-thiazolyl)-amides en tant qu'inhibiteurs de la gsk-3

Info

Publication number
MA30419B1
MA30419B1 MA31393A MA31393A MA30419B1 MA 30419 B1 MA30419 B1 MA 30419B1 MA 31393 A MA31393 A MA 31393A MA 31393 A MA31393 A MA 31393A MA 30419 B1 MA30419 B1 MA 30419B1
Authority
MA
Morocco
Prior art keywords
gsk
thiazolyl
amide derivatives
inhibitors
disease
Prior art date
Application number
MA31393A
Other languages
English (en)
Inventor
Gil Ana Martinez
Morera Ana Castro
Padilla Miguel Medina
Aparicio Ester Martin
Cascon Mercedes Alonso
Huerta Ana Fuertes
Rico Maria Luisa Navarro
Puerto Maria Jose Perez
Monte Millan Maria Del
Original Assignee
Noscira Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38069119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30419(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Noscira Sa filed Critical Noscira Sa
Publication of MA30419B1 publication Critical patent/MA30419B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)

Abstract

La présente invention a trait à l'utilisation des dérivés de N-(2-thiazolyl)-amide pour le traitement et / ou la prophylaxie d'une maladie ou une condition dans laquelle la glycogène synthase kinase 3 (GSK-3) est impliquée, en particulier les maladies neurodégénératives, telles que la maladie d'Alzheimer, ou le diabète non insulinodépendant.
MA31393A 2006-04-28 2008-11-20 Utilisation de derives de n-(2-thiazolyl)-amides en tant qu'inhibiteurs de la gsk-3 MA30419B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06380099A EP1849785A1 (fr) 2006-04-28 2006-04-28 Dérivés de N-(2-Thiazolyl)-amide en tant qu'inhibiteurs de GSK-3
US87838607P 2007-01-04 2007-01-04

Publications (1)

Publication Number Publication Date
MA30419B1 true MA30419B1 (fr) 2009-05-04

Family

ID=38069119

Family Applications (2)

Application Number Title Priority Date Filing Date
MA31393A MA30419B1 (fr) 2006-04-28 2008-11-20 Utilisation de derives de n-(2-thiazolyl)-amides en tant qu'inhibiteurs de la gsk-3
MA31392A MA30418B1 (fr) 2006-04-28 2008-11-20 Utilisation de derives de n-(2-thiazolyl)-amides en tant qu'inhibiteurs de la gsk-3

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA31392A MA30418B1 (fr) 2006-04-28 2008-11-20 Utilisation de derives de n-(2-thiazolyl)-amides en tant qu'inhibiteurs de la gsk-3

Country Status (18)

Country Link
US (2) US20090221647A1 (fr)
EP (3) EP1849785A1 (fr)
JP (2) JP2009535320A (fr)
KR (2) KR20090015940A (fr)
CN (2) CN101432283A (fr)
AR (1) AR060675A1 (fr)
AU (2) AU2007245625B2 (fr)
BR (2) BRPI0711080A2 (fr)
CA (2) CA2650326A1 (fr)
IL (2) IL194932A0 (fr)
MA (2) MA30419B1 (fr)
MX (2) MX2008013764A (fr)
NO (2) NO20084924L (fr)
NZ (2) NZ572840A (fr)
RU (2) RU2429237C2 (fr)
UY (1) UY30312A1 (fr)
WO (2) WO2007125110A1 (fr)
ZA (1) ZA200809954B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR063028A1 (es) 2006-10-06 2008-12-23 Banyu Pharma Co Ltd Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
RU2009119181A (ru) 2006-10-21 2010-11-27 Эбботт Гмбх Унд Ко.Кг (De) Гетероциклические соединения и их применение в качестве ингибиторов гликогенсинтаза-киназы-3
EP2020232A1 (fr) * 2007-08-03 2009-02-04 Zeltia, S.A. Dérives de N-(1-thiazolyl)-amide pour traiter l'obésité, le diabète et des maladies cardiovasculaires
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
US8835644B2 (en) 2009-03-20 2014-09-16 University Of Virginia Patent Foundation Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012040170A2 (fr) * 2010-09-20 2012-03-29 University Of Virginia Patent Foundation Compositions et méthodes de traitement de la tuberculose
US9266855B2 (en) 2010-09-27 2016-02-23 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (fr) 2011-03-08 2016-06-01 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
EP2682119A1 (fr) * 2012-07-03 2014-01-08 Université Libre de Bruxelles Dérivés N-hétérocycles aromatiques à utiliser comme médicament
ES2514093B1 (es) * 2013-03-25 2015-08-17 Consejo Superior De Investigaciones Cientificas (Csic) Compuestos neurogénicos basados en melatonina y su uso en el tratamiento de enfermedades del sistema nervioso
US20200216435A1 (en) * 2017-06-14 2020-07-09 European Molecular Biology Laboratory Bicyclic heteroaromatic amide compounds for use in therapy
US20230020507A1 (en) * 2019-10-04 2023-01-19 Parenchyma Biotech Inc. Compound and use thereof in treating autoimmune diseases
CN114555583B (zh) * 2019-10-04 2025-01-28 帕连齐玛生物技术株式会社 化合物及其在治疗自身免疫性疾病中的用途
KR102576382B1 (ko) * 2022-06-21 2023-09-12 파렌키마바이오텍 주식회사 신규 화합물 및 이의 자가면역질환 치료 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1212326A (en) * 1969-06-18 1970-11-11 Parke Davis & Co New 5-nitro-4-thiazoline-3-acetamide compounds and methods for their production
EP0566138B1 (fr) * 1992-04-17 1998-11-18 Hodogaya Chemical Co., Ltd. Amino thiazoles et leur utilisation comme fongicides
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
AU2010601A (en) * 1999-12-16 2001-07-03 Novartis Ag Organic compounds
AU2001230026A1 (en) * 2000-02-04 2001-08-14 Novo-Nordisk A/S 2,4-diaminothiazole derivatives
ATE315555T1 (de) * 2001-05-11 2006-02-15 Pfizer Prod Inc Thiazolderivate und ihre verwendung als cdk- inhibitoren
CN100357283C (zh) * 2002-04-02 2007-12-26 中国科学院上海药物研究所 一类甲硫氨酰氨肽酶抑制剂
SE0201194D0 (sv) * 2002-04-19 2002-04-19 Astrazeneca Ab New compounds
CA2499329C (fr) * 2002-10-03 2009-04-21 F. Hoffmann-La Roche Ag Indole-3-carboxamides servant d'activateurs de glucokinase (gk)
US6737382B1 (en) * 2002-10-23 2004-05-18 Nippon Soda Co. Ltd. Insecticidal aminothiazole derivatives
WO2005014591A1 (fr) * 2003-07-15 2005-02-17 L'oreal 2-acylamino ou 2-sulfonylamino-1, 3-thiazoles en tant qu'agents de couplage pour la coloration d'oxydation de fibres keratiniques
CN100545161C (zh) * 2003-08-15 2009-09-30 中国科学院上海药物研究所 一类杂环衍生物、制备方法及其用途
EP1532980A1 (fr) 2003-11-24 2005-05-25 Novo Nordisk A/S Carboxamides d'indole n-heteroarylé et leurs analogues, utiles comme des activateurs de glucokinase pour le traitement de diabetes

Also Published As

Publication number Publication date
ZA200809954B (en) 2010-02-24
BRPI0711080A2 (pt) 2011-08-23
UY30312A1 (es) 2007-09-28
EP2019828A1 (fr) 2009-02-04
WO2007125110A1 (fr) 2007-11-08
MX2008013765A (es) 2009-01-22
NZ572840A (en) 2011-11-25
RU2008146995A (ru) 2010-06-10
KR20090015940A (ko) 2009-02-12
NO20084923L (no) 2008-11-24
NO20084924L (no) 2008-11-24
RU2450000C2 (ru) 2012-05-10
EP1849785A1 (fr) 2007-10-31
JP2009535321A (ja) 2009-10-01
JP2009535320A (ja) 2009-10-01
US20090221647A1 (en) 2009-09-03
US20090192204A1 (en) 2009-07-30
IL194932A0 (en) 2009-08-03
CA2650326A1 (fr) 2007-11-08
IL194937A0 (en) 2009-08-03
CA2650323A1 (fr) 2007-11-08
RU2429237C2 (ru) 2011-09-20
BRPI0711078A2 (pt) 2011-08-23
AU2007245625B2 (en) 2012-07-05
EP2019829A1 (fr) 2009-02-04
MX2008013764A (es) 2009-01-22
CN101432283A (zh) 2009-05-13
MA30418B1 (fr) 2009-05-04
WO2007125109A1 (fr) 2007-11-08
AU2007245624A1 (en) 2007-11-08
AU2007245625A1 (en) 2007-11-08
CN101432282A (zh) 2009-05-13
KR20090023585A (ko) 2009-03-05
AR060675A1 (es) 2008-07-02
NZ572790A (en) 2010-12-24
RU2008146993A (ru) 2010-06-10

Similar Documents

Publication Publication Date Title
MA30419B1 (fr) Utilisation de derives de n-(2-thiazolyl)-amides en tant qu'inhibiteurs de la gsk-3
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
EP1841426A4 (fr) Carbinamines tertiaires incluant des heterocycles substitues, agissant en tant qu'inhibiteurs de la beta-secretase et utilisees dans le traitement de la maladie d'alzheimer
WO2007016228A3 (fr) Composés et compositions en tant qu’inhibiteurs de kinase de protéine
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
MA30405B1 (fr) Derives de 4-benzylphtalazinone substitues en 2 en tant qu'antagonistes des histamines hl et h3
WO2006099379A3 (fr) Derives de benzazole, compositions et methodes d'utilisation des derives comme inhibiteurs de la b-secretase
MA30526B1 (fr) Inhibiteurs de prolyle hydroxylase
EP1888066A4 (fr) Aminocyclohexanes en tant qu'inhibiteurs de dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
TNSN02014A1 (fr) Composes nouveaux agonistes de ppar et compositions les contenant
WO2007011833A3 (fr) Inhibiteurs de spiropiperidine beta-secretase pour le traitement de la maladie d'alzheimer
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
WO2008030412A3 (fr) Inhibiteurs de la spiropipéridine bêta-sécrétase pour le traitement de la maladie d'alzheimer
TNSN01145A1 (fr) Derives d'imidazole a noyau aryle ou heteroaryle condense, et compositions les contenant.
EP1962601A4 (fr) Amino-piperidines fusionnees en tant qu'inhibiteurs de la dipeptidyl peptidase-4 pour le traitement ou la prevention du diabete
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
EP1638950A4 (fr) Derives de cyclohexylglycine servant d'inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
EP1921917A4 (fr) Aminopiperidines fusionnees utilisees comme inhibiteurs de dipeptidyl-peptidase-iv pour le traitement ou la prevention du diabete
MA30900B1 (fr) Anticorps d'agonistes anti-notch3 et leur utilisation dans le traitement de maladies liées à notch3
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
MA31457B1 (fr) N-(2-(hetaryl)aryl)arylsulfonamides et n-(2-(hetaryl)hetaryl)arylsulfonamides
WO2006044497A3 (fr) Composes de spiropiperidine utilises comme inhibiteurs de beta-secretase en vue du traitement de la maladie d'alzheimer
NO20075154L (no) Formuleringer av en src/abl-inhibitor